PENTRU INFORMAȚII SUPLIMENTARE, VĂ RUGĂM SĂ ACCESAȚI ARTICOLUL COMPLET:
Ziegler D, Tesfaye S, Spallone V, Gurieva I, Al Kaabi J, Mankovsky B, Martinka E, Radulian G, Nguyen TK, Stirban AO, Tankova T, Varkonyi T, Freeman R, Kempler P, Boulton AJM. Screening, diagnosis and management of diabetic sensorimotor polyneuropathy in clinical practice: International expert consensus recommendations. Diabetes Res Clin Pract. 2021 Sep 18:109063. doi: 10.1016/j.diabres.2021.109063. Epub ahead of print. Accesibil online aici.
REFERINȚE
1. Candido R, Musacchio N, Manicardi V,Nicolucci A, Rossi MC, Di Cianni G, Mannino D, Di Bartolo P. Valutazione degli indicatori AMD di qualità dell’assistenza al diabete di tipo 1 e 2 in Italia. Annali AMD 2020. Accesibil online aici.
2. .D‘Amato C, Morganti R, Greco C,Di Gennaro F,Cacciotti L, Longo S, Mataluni G, Lauro D, Marfia GA,Spallone V.Diabetic peripheral neuropathic pain is a stronger predictor of depression than other diabetic complications and comorbidities. Diab Vasc Dis Res. 2016 Nov;13(6):418-428
3. .Jin HY, Moon SS,Calcutt NA. Lost in Translation? Measuring Diabetic Neuropathy in Humans and Animals. Diabetes Metab J. 2021 Jan;45(1):27-42.
4.Petropoulos IN,Ponirakis G,Ferdousi M, Azmi S,Kalteniece A, Khan A, Gad H, Bashir B, Marshall A, Boulton AJM, Soran H, Malik RA. Corneal Confocal Microscopy:A Biomarker for Diabetic Peripheral Neuropathy.Clin Ther. 2021 May 5:S0149-2918(21)00197-1.
5.Seferovic JP, Pfeffer MA, Claggett B, Desai AS, de Zeeuw D, Haffner SM, McMurray JJV, Parving HH, Solomon SD, Chaturvedi N. Three-question set from Michigan Neuropathy Screening Instrument adds independent prognostic information on cardiovascular outcomes: analysis of ALTITUDE trial. Diabetologia. 2018 Mar;61(3):581-588.
6.Spallone V,Valensi P. SGLT2 inhibitors and the autonomic nervous system in diabetes:A promising challenge to better understand multiple targetimprovement.Diabetes Metab. 2021Jul;47(4):101224.
7.Spallone V,Morganti R, D‘Amato C, GrecoC,Cacciotti L, Marfia GA.Validation of DN4 as a screening tool for neuropathic pain in painful diabetic polyneuropathy.Diabet Med. 2012May;29(5):578-85.
8.Bouhassira D, Letanoux M, Hartemann A. Chronic pain with neuropathic characteristics in diabetic patients: a French cross-sectional study. PLoSOne. 2013 Sep 13;8(9):e74195.
9.Meisinger C, Bongaerts BWC, Heier M, Amann U, Kowall B, Herder C, Rückert-Eheberg IM, Rathmann W, Ziegler D. Neuropathic pain is not adequately treatedin the older general population: Results from the KORA F4 survey. Pharmacoepidemiol DrugSaf. 2018 Jul;27(7):806-814.
10.Happich M, Schneider E, Boess FG, Wilhelm S, Schacht A, Birklein F, Ziegler D. Effectiveness of duloxetine compared with pregabalin and gabapentin in diabetic peripheral neuropathic pain: results from a German observational study. Clin J Pain. 2014Oct;30(10):875- 85.
11.Margolis JM, Princic N, Smith DM, AbrahamL, Cappelleri JC, Shah SN, Park PW. Economic Impactof Adherence to Pain Treatment Guidelines in Chronic Pain Patients. Pain Med. 2019Oct1;20(10):1907-1918.
12.Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P; Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010Oct;33(10):2285-93.
13.Pop-Busui R, Boulton AJ, Feldman EL, Bril V,Freeman R, Malik RA, Sosenko JM, Ziegler D. Diabetic Neuropathy: A Position Statement by the American DiabetesAssociation. DiabetesCare.2017Jan;40(1):136-154